New Focus by NCI’s CPTC Targets Vendors to Bring Deliverables to Research Community

Originally posted: October 30, 2008 By Tony Fong GenomeWeb ProteoMonitor

CAMBRIDGE, Mass. — With its technology-development programs well under way, the National Cancer Institute’s Clinical Proteomic Technologies for Cancer initiative has begun turning its attention to the big vendor community.

Its aim is to get those companies tools into the research community and to invest big commercial players more heavily into CPTC’s efforts, its director, Henry Rodriguez, told ProteoMonitor this week.

When it was created two years ago, CPTC initially focused on boot-strapping its three programs directed at technology development: the Clinical Proteomic Technology Assessment for Cancer, the Advanced Proteomic Platforms and Computational Sciences, and the Proteomic Reagents and Resource Core.

But as these programs have enabled materials, such as antibodies, reagents, and protocols, to begin making their way into the CPTC’s pipeline, the organization last year began to shift its emphasis to also include vendors. The initial target was smaller shops and at its second annual meeting, held here this week, some of the results from that effort were highlighted as a number of small proteomics companies presented technology developed with funding by CPTC.

Now, the push will be directed at the larger commercial vendors, Rodriguez said.

“We tried to emphasize the private-public partnerships” at this meeting, Rodriguez said. “Even though we’re producing the science, we’re also producing materials as a program. … And while we give them back to the community, it quickly dawned on us that the community may already have some platform that is commercially sold.

“So we said, ’Let’s put out solicitations now to the small-business community with these platforms and at the same time, if they’re successful, they will start to adopt the reagents that we’re developing and that could go back to the community,’” he said.

To do so, his office last year worked with NCI’s small-business office to issue a solicitation to encourage small businesses to adapt their own platforms to techniques and methods developed by the CPTC, and to use materials produced by the CPTAC group.

The result can be seen in work performed by, for instance, Allele Biotechnology in San Diego, which used a Phase 1 SBIR grant from the NCI to develop a panel of antibodies with high affinity and specificity against 10 cancer-related antigens, company CEO Jiwu Wang said during a presentation at the CPTC conference. The antibodies, he said, can be formatted to be specific to mice, rabbit, and other model organisms, or be developed into full IgG antibodies.

Improving MS Capability

Now as the CPTC shifts its attention to larger vendors, much of its attention will be directed at mass spectrometry. CPTAC, which comprises five teams and a host of collaborators, is in the process of publishing three papers on work it has done studying reproducibility with mass spectrometers [See PM 09/04/08]. When those are published, CPTC anticipates hosting a teleconference with the major mass-spec vendors “to say to them, ‘Here are the things that we’re producing that add a lot of value. What are the needs that you have … that either we are addressing that we can work with you, or that we’re not addressing to see if we can also build that into the program?’” Rodriguez said.


--------------------------------------------------------------------------------
“What we can bring to [the table] is to say, “Here’s a program with this network. It doesn’t focus on one platform, but we recognize that universally, across them all, we can develop some very nice metrics that add not just [an] advantage to one … but advantages across the board.’”

--------------------------------------------------------------------------------


Even before CPTC was created, NCI met with mass-spec vendors to get their views on what such a project could do for that community. What the agency heard, for example, was that manufacturers needed help in improving, from a computational approach, their instruments’ detection and identification capabilities, Rodriguez said.

To be sure, each vendor has its own R&D personnel working on such problems, but CPTC offers a greater breadth of researchers working on methods to improve the instruments, Rodriguez said, citing work by Richard Smith at Pacific Northwest National Laboratory.

At the two-day conference, Smith presented research being done by his lab on a high-throughput platform based on a liquid chromatography coupled with an ion mobility spectrometer that is in turn interfaced with a time-of-flight mass spec. In addition to improved throughput, the platform offers greater sensitivity, robustness, and quantitative capabilities for biomarker discovery, verification, and preclinical validation, Smith said.

“What we can bring to [the table] is to say, ‘Here’s a program with this network,’” Rodriguez said. “It doesn’t focus on one platform, but we recognize that universally, across them all, we can develop some very nice metrics that add not just [an] advantage to one … but advantages across the board.”

CPTC also plans to meet with the major reagent vendors in order to get them into the fold, he added.

No Discovery Work Here

CPTC is one of several federal initiatives and programs focusing on proteomics to tackle diseases such as cancer and neurological ailments, and to address biodefense issues. But unlike other federal efforts, CPTC is directed not at discovery work but at improving a proteomics scientist’s workflow: its goal is to provide solutions to challenges such as reproducibility, standards, and poor study designs that have hindered the field.

CPTC would like to take the technologies developed through its programs to other proteomics programs being funded by the NIH as well as other agencies, and say, “’Here’s a robust workflow, a methodology that we know can give you give you the power to identify where variability occurs, and if you can account for it, we’re there; if you cannot eliminate it, we can tell you how to best deal with it,’” Rodriguez said.

A more recent challenge in proteomics Rodriguez and others have identified is specimen quality, which can introduce biases into an experiment.

CPTC is focused on the analytical and pre-analytical aspects of research, but is also working with the NCI’s Office of Biorepositories and Biospecimen Research to overcome that challenge by developing common protocols for specimen collection and handling, Rodriguez said.

Papers and Antibodies Coming Soon

During the meeting, an update was also provided on CPTAC’s continuing work on mass-spec reproducibility. To date, the group has performed six studies, with the first looking at a 20-protein mixture and eight instrument types, and later studies steadily progressing to a more complex yeast-reference mixture and the use of ion trap mass specs.

With each progressive study, the group incorporated more refined standard operating procedures such as standardized chromatography and common statistical phase distribution.

While Daniel Liebler, who is heading the CPTAC team at Vanderbilt University, one of five CPTAC teams, declined to discuss in detail the findings from the studies, he said during a presentation that one of the deliverables from the research so far is that the yeast proteome potentially could provide a model for biomarker research via a shotgun proteomics platform.

The CPTAC teams are preparing three papers on their research: one describing their findings with the yeast proteome; another describing metrics that can serve as reference points for mass specs; and one describing the work they did looking at variability in peptide and protein identification between and across systems.

Finally, Tara Hiltke, program manager at CPTC, provided an update on its antibody initiative [See PM 11/29/07]. The antibodies resulting from its first funding round will become available to the public by the end of the year, she said. A third funding round to develop antibodies against about 40 antigens will be announced in January.

Memory at One Year after Sichuan Earthquake that Killed 100 Thousand People

It was exactly one year ago the ground shook wildly for more than 1 minute, kind of stopped for a breather, then another wave…it felt much longer when I, my 4 and 5 year old sons, my wife and her parents were on 18th floor in Xinanmen area of city Chengdo, some 50-100 miles from the center. All I was thinking was that this would stop, another 5 seconds and it would stop. I didn’t wake up the kids, who were too tired from playing all day and so deep in sleep to wake up amid the violent shaking.

Flash back:
32 years ago as a young boy myself I was waken up by the thud from my bike's falling on the wooden floor during the infamous Tangshan earthquake of similar strength as the Sichuan quake, which killed 200-400 thousand people within 45 seconds.

15 years ago I was not asleep when a ~6 quake shook L.A.

I seemed to be close to where the actions are for most quakes and such things, and of course 20 years ago, in the Tiananmen square where bullets were flying as close as 20 yards away.

Back to reality:
The ground was till moving, the building tilting, noise from the street became a loud roar even to people up on 18th floor. All phone lines were dead, honestly, this time I did not feel the threat of life, not even for one second. It could be the times I have experienced this, or it could simply be that I refused to think that now that I had my family, my responsibilities to them and to my company, my employees, and my goals still to be reached. No, not now, not yet.

The following 4 days we stayed in the same city, witnessed the desperation, heard the horrible news from 24 hour TV, and saddened to learn that tens of thousands of school children were gone. I went on to Nanjing before the airport was taken over by cargo planes and finished my plan of teaching at Nanjing Medical University where I was appointed a visiting professor. It was all but an experience for me, but for those who did not get to move ever again from that minute on 5.12, it concluded their journey in this world.

There is nothing that can ease the pain their surviving families must be suffering right this moment, exactly a year after.

May peace be with them.

One Alleler
www.allelebiotech.com

Flickr

This is a test post from , a fancy photo sharing thing.

Allele will honor Oprah's KFC coupon to its customers!

Hey grads and postdocs, here you go and you are welcome:
http://www.allelebiotech.com/allele3/promotion.php

While you are there, check out our Special Chemical product group launched today, coinciding with the KFC chicken coupons! Yes!! It has only 4 products now, will be a dozen soon, then a few hundreds to thousands in a few months if all goes well. If not, just the oligo chemicals available now should already provide tremendous value to oligo producers because iPCR, Real-time PCR are getting more and more used, requiring large number of probes with these modifications we products can do, but at previously unthinkable low prices. Read more here.

another update of www.allelebiotech.com

with new front page buttons, product families on the left, and hot buying guide on the right. check out the cool looks, out of thousands products in the most active research areas in molecular and cell biology, there ought to be something you need, and at much lower prices.

Introducing cost efficiency to research!

A big anniversary and it is quiet. Here is my contribution to the celebration.

On the Anniversary of a "Flagship" University for Democracy and Science in the Most Populous Country

和谐当奴隶 加帖在 猫眼看人 【凯迪网络】 http://www.kdnet.net
小绵羊呀真可爱！
会吃奶来会撒娇，
没有脾气不乱吠，
真是可爱的小可爱
This is a description of today’s Peking University or Beida, and it hurt me to cite it like that.

I want to say as a Beida aluminum, that what the most important thing you come out of Beida is not the name of Beida that can be forever associated with your name, not the knowledge you worked so hard to grasp, not what your teachers tried to put into your mind, it is the spirit of freedom and courage. If you understand the meaning of freedom, and by excising your own you help with freedom of all people of this country and the whole world. Freedom means your right to think out of your mind, not your bind or behind; your tendency to criticize, not praise; your ability to show grace under fire, not lose your dignity and humanity when under pressure; and bravery to speak your mind, not somebody else’s. Do this, you have a chance to fulfill your life not with a bigger salary of a higher ranking title, but your true satisfactory of being a good and decent person and an upright character that yield to nobody but truth and pursue of truth. At the end of your life, you will know it has meant something to those who you love and those who love you and all of your fellow human beings.


Jiwu Wang, Ph.D.
Beida 89 Biochemistry
Written at the anniversary of my beloved college.